UCB's Board of Directors elected New Chairman for 2012
Brussels (Belgium), September 23, 2011 – regulated information – UCB announces that UCB’s Board of Directors has elected Gerhard Mayr as new chairman of the Board of Directors as of May 2012. Gerhard Mayr will follow the current Chairman of the Board, Karel Boone, in this position when Karel Boone’s term is ending in April 2012 as he reached the age limit of 70.
Karel Boone commented: “I am delighted to hand over to Gerhard Mayr. I am convinced that all internal and external stakeholders will give him their full support. With his excellent knowledge of UCB and his exceptional experience especially in the innovative pharma industry he will continue to support the transformation of UCB becoming the patient-centric biopharma leader.”
Gerhard N. Mayr, member of UCB’s Board of Directors since 2005 is Independent Director and Member of the Remuneration and Appointments Committee He is also member of the Audit Committee. A native of Austria, Gerhard Mayr received a master's degree in chemical engineering from the Swiss Federal Institute of Technology (Zurich, Switzerland) in 1969, and a master of business administration degree from Stanford University in 1972. In March, 2004, he retired as executive vice president of pharmaceutical operations at Eli Lilly & Company after 32 years of service. He had been responsible for global pharmaceutical operations and sales and marketing worldwide at Lilly - a leading innovation-driven corporation. Gerhard Mayr is past chairman of both the International Executive Committee and the Europe Committee of the Pharmaceutical Research Manufacturers of America. He was a board member of the European Federation of the Pharmaceutical Industry from 1995-97 and 2000-2002. Gerhard Mayr is a Member of the Board of Lonza Group Ltd.
Karel Boone is Member of UCB’s Board of Directors since 2000 and Chairman since 2008, he is also member of the Audit Committee and member of the Remuneration and Nomination Committee. Commercial Engineer (KUL), Karel Boone started in 1966 as an executive member of the Board of Directors of Lotus Bakeries (Lotus Biscuits at this time) and became CEO in 1974 when Lotus Biscuits merged with Corona. He was also Executive Chairman of the Board of Directors from 1992 until 2006 when he became non-Executive Chairman of the Board of Directors. He is a member of the following Boards of Directors: Banque Degroof, Vandemoortele (Chairman). He was active in professional organizations and has been Chairman of the Federation of Belgian Companies.
For further information
Antje Witte, Investor Relations, UCB
T +32.2.559.9414, firstname.lastname@example.org
Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, Michael.email@example.com
France Nivelle, Global Corporate Communications, UCB
M: +32.47.549.4001, firstname.lastname@example.org
Notes to the editor
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).
UCB Forward-looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.
Stay up-to-date on the latest news and information from UCB